| Vol. 12.05 – 12 February, 2021 |
| |
|
|
| Scientists identified BCL-2 and IKKB dependencies in clinically relevant enzalutamide-resistant prostate cancer cells in vitro and in vivo. [Clinical Cancer Research] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Potent and direct androgen receptor-mediated induction of ELOVL fatty acid elongase 5 (ELOVL5), an enzyme that catalyzes fatty acid elongation, was demonstrated in prostate cancer cells, xenografts, and clinical tumors. [Cancer Research] |
|
|
|
| A systematical analysis of long-chain fatty acyl-CoA synthetases (ACSLs) levels and the amount of fatty acyl-CoAs illustrated that ACSL1 were significantly associated with the levels of a broad spectrum of fatty acyl-CoAs, and were elevated in human prostate tumors. [Oncogene] |
|
|
|
| Functional analyses identified USP16, known as a deubiquitinase, was strongly correlated with the c-Myc gene signature. Depletion of USP16 was shown to significantly suppress the growth of prostate cancer cells both in vitro and in vivo. [Journal of Experimental & Clinical Cancer Research] |
|
|
|
| Researchers explored whether the anti-prostate cancer activity of the ARATs abiraterone and enzalutamide was enhanced by metformin. [Cancers] |
|
|
|
| Scientists interrogated both proteomics and transcriptomic alterations stimulated in the AR antagonist/anti-androgen treated androgen-dependent cell model in comparison with androgen-independent/castration-resistant cell model. [Cancers] |
|
|
|
| Investigators indicated that V-ATPase dysregulation was directly linked to both hormone responsive and castrate-resistant prostate cancer via impact on androgen receptor function. [Molecular Cancer Therapeutics] |
|
|
|
| Scientists identified potential early driver genes responsible for castration-resistant prostate cancer development. [Prostate Cancer and Prostatic Diseases] |
|
|
|
| Researchers produced gallium-66 suitable for radiolabeling, and investigated the imaging properties of gallium-66 labeled gastrin-releasing peptide receptor (GRPR)-antagonist NOTA-PEG2-RM26 for later-time point PET-imaging of GRPR expression. In vitro, [66Ga]-NOTA-PEG2-RM26 was characterized in GRPR-expressing PC-3 prostate cancer cells. [Scientific Reports] |
|
|
|
|
| The authors aim to improve prostate cancer detection, management and outcomes, including understanding the fundamental biology at all stages of the disease. [Nature Reviews Disease Primers] |
|
|
|
| Investigators summarize the current knowledge on androgen indifferent prostate cancer (AIPC) variants, including the current understanding of the clinical, morphologic, and molecular features as well as current therapeutic approaches. They also explore emerging therapies and biomarkers aimed at improving outcomes for men with AIPC. [Prostate Cancer and Prostatic Diseases] |
|
|
|
|
| The Janssen Pharmaceutical Companies of Johnson & Johnson announced results from the final analysis of the Phase III TITAN study, which demonstrated the continued statistically significant benefit of the addition of apalutamide to androgen deprivation therapy (ADT) in overall survival in patients with metastatic castration-sensitive prostate cancer, regardless of extent of disease, when compared to placebo plus ADT. [Janssen Pharmaceutical Companies of Johnson & Johnson] |
|
|
|
|
| May 17 – 21, 2021 Virtual |
|
|
|
|
|
| The University of Texas MD Anderson Cancer Center – Houston, Texas, United States |
|
|
|
| The University of British Columbia – Vancouver, British Columbia, Canada |
|
|
|
| Oslo University Hospital – Oslo, Norway |
|
|
|
| Vall D’Hebron Institute of Oncology – Barcelona, Spain |
|
|
|
| Harvard Medical School – Boston, Massachusetts, United States |
|
|
|
|